Glenmark inks pact with SaNOtize to produce, market anti-COVID-19 nasal spray in India, other countries
The Hindu
Available in the form of a nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs
Canadian biotech firm SaNOtize Research & Development Corp. has entered into an exclusive long term agreement with Glenmark Pharmaceuticals Ltd for the manufacturing, marketing and distribution of its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India. Glenmark will also be handling other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. “In March 2021, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms,” Glenmark said in a statement.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












